157 related articles for article (PubMed ID: 38169532)
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein.
Shen J; Hong L; Chen L
Biochem Biophys Res Commun; 2020 Apr; 524(3):683-688. PubMed ID: 32033748
[TBL] [Abstract][Full Text] [Related]
3. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
4. NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.
Gao M; Herlinger AL; Wu R; Wang TL; Shih IM; Kong B; Rangel LBA; Yang JM
Aging (Albany NY); 2020 May; 12(10):9275-9291. PubMed ID: 32412910
[TBL] [Abstract][Full Text] [Related]
5. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
6. High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.
Zhu L; Feng H; Jin S; Tan M; Gao S; Zhuang H; Hu Z; Wang H; Song Z; Lin B
Tumour Biol; 2017 Jul; 39(7):1010428317711655. PubMed ID: 28671040
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis.
Xiang T; Tang J; Li L; Peng W; Du Z; Wang X; Li Q; Xu H; Xiong L; Xu C; Le X; Wei X; Yu F; Li S; Xiao Q; Luo B; Xiang X; Huang A; Lin Y; Ren G; Tao Q
Theranostics; 2019; 9(26):8182-8195. PubMed ID: 31754389
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
9. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
10. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
11. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
[TBL] [Abstract][Full Text] [Related]
12. BCL6 promotes glioma and serves as a therapeutic target.
Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
[TBL] [Abstract][Full Text] [Related]
13. An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.
Sultan M; Nearing JT; Brown JM; Huynh TT; Cruickshank BM; Lamoureaux E; Vidovic D; Dahn ML; Fernando W; Coyle KM; Giacomantonio CA; Langille MGI; Marcato P
Mol Oncol; 2021 Aug; 15(8):2046-2064. PubMed ID: 33932086
[TBL] [Abstract][Full Text] [Related]
14. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
15. miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.
Shan W; Li J; Bai Y; Lu X
Tumour Biol; 2016 Apr; 37(4):5203-11. PubMed ID: 26553360
[TBL] [Abstract][Full Text] [Related]
16. A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia.
Zhang L; Wu M; Guo W; Zhu S; Li S; Lv S; Li Y; Liu L; Xing Y; Chen H; Liu M; Peng S; Chen Y; Yi Z
Biomed Pharmacother; 2023 Oct; 166():115358. PubMed ID: 37634473
[TBL] [Abstract][Full Text] [Related]
17. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
Zacharchenko T; Kalverda AP; Wright SC
Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
[TBL] [Abstract][Full Text] [Related]
19. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.
He J; Wu M; Xiong L; Gong Y; Yu R; Peng W; Li L; Li L; Tian S; Wang Y; Tao Q; Xiang T
Clin Epigenetics; 2020 Jun; 12(1):82. PubMed ID: 32517789
[TBL] [Abstract][Full Text] [Related]
20. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
